International HBV Meeting
1-5 October, 2019
Melbourne, Australia
The ENYO Pharma team will be present in Melbourne in October to present, in collaboration with Pr. André’s Inserm team, a poster entitled “Interplay and Recruitment of FXR and HBx on cccDNA and Role on Viral Transcription” describing FXR mechanism of action in HBV inhibition.
ENYO PHARMA ANNOUNCES NEW CFO AND PROVIDES CLINICAL PIPELINE UPDATE
Lyon, France, September 19th, 2019 – ENYO Pharma, a private clinical stage biotechnology company developing innovative drug candidates, today announced the appointment of Jonathan Lieber as Chief Financial Officer. ENYO Pharma also provided a pipeline update today with a focus on EYP001 (Vonafexor, proposed INN), the Company’s FXR agonist that is currently in Phase II clinical development in both Hepatitis B (HBV) and Nonalcoholic Steatohepatitis (NASH).
New offices in Lyon
From Monday, September 16th, the ENYO Pharma teams will invest new premises in the BIOPARC which is being set up in LYON 8th. This is the opportunity to expand and benefit from the emulation that BIOPARC will create.
2019 EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY conference
27th of Sept – 1st of Oct
Barcelona, Spain
ENYO Pharma will attend the ESMO conference in order to raise awareness of it novel, potent chemistry which induces Immunogenic Cell Death in multiple tumour types and inhibits tumor growth in animal models.
Paris NASH meeting
11-12 July, 2019
Paris
ENYO Pharma was present in Paris during the NASH meeting to meet the other NASH actors and discuss with them about our last results.
Latest Press Release 